Drug discovery and development
The latest chemistry news and research on drug discovery and development, including cancer drugs, antibiotics, vaccines and drug screening, from the Royal Society of Chemistry's magazine, Chemistry World
-
ResearchCrystal structure prediction reaches new heights with axitinib
Computational strategy predicts complex polymorphs and distinguishes salts from co-crystals
-
BusinessUK agrees higher drug prices to secure zero-tariff deal with US
NHS could pay up to 25% more for innovative drugs, but exports will be tariff free for three years
-
OpinionWhat’s on your lab technology wish list?
Once-magical tools are now mundane. What will the next miracles be?
-
ResearchRevived claims that antibiotics don’t kill bacteria with reactive oxygen prove controversial
Researchers say that multiple lines of evidence for hypothesis have now been undermined
-
NewsCould Crispr cure HIV?
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at evading eradication
-
OpinionA robotic helping hand
Mechanical labmates are making huge progress, but there are still big challenges to overcome
-
ResearchAI-designed antibodies target antigens with atomic precision
Epitope-binding proteins designed from scratch by generative AI model
-
ResearchAI cut development time of antibiotic that spares gut-friendly bacteria by two years
Animal tests show promise to target invasive strain of E. coli but approval for use in humans is still years away
-
BusinessPfizer and Novo Nordisk’s battle over Metsera
Lawsuits fly in bidding war over developer of next generation weight loss drugs
-
ResearchNanobodies from alpacas and llamas could hold the key to a universal antivenom
Novel nanobody mix protects against 17 African snake species
-
BusinessNovartis spends on deals to offset patent losses
$12 billion Avidity acquisition is the latest pipeline-pumping transaction
-
ResearchThis fragment-based drug discovery library is designed to be sociable
Study targets a key bottleneck in hit to lead optimisation by designing fragments that are both structurally diverse and easy to elaborate
-
WebinarSYNTHIA for chemists: faster route design
Discover how SYNTHIA accelerates retrosynthesis by helping chemists design, compare and refine routes with customisable filters and commercial building blocks
-
ResearchUltrapotent thrombin inhibitor combines peptide fragments from a trio of blood-sucking organisms
Hybrid molecule featuring leech, tsetse fly and flea peptide fragments binds thrombin at three sites
-
WebinarDeveloping a CITK protein degrader using the QuicTPD™ platform
Learn about the latest technology to accelerate the design of cancer treatments
-
BusinessArvinas and Pfizer seek a new home for protein degrader drug
Companies offer bifunctional cancer drug vepdegestrant to new partners after disappointing trial results
-
BusinessNovo Nordisk’s new chief cuts 9000 jobs
Danish firm shifts strategy after struggling to capitalise on its weight loss drugs
-
OpinionIs UK pharma really ‘uninvestable’?
Merck & Co, AstraZeneca (AZ) and Eli Lilly pulling UK projects highlights the precarious position of the country’s life sciences industry
-
BusinessUK loses life sciences investment as pharma companies halt expansion plans
Industry seeks greater share of healthcare spending to support innovation
-
WebinarIon suppression correction and normalisation in metabolomics
Join us to learn new ways to improve data consistency with mass spectrometry